Pharmacokinetic characteristics of MK-5890 in a Rhesus monkey toxicology study and in a Ph1 clinical study
| Summary mean (±SE) pharmacokinetic parameters in Rhesus monkey after single bolus IV dose of MK-5890 in a toxicology study | Summary geometric mean (%GCV) serum pharmacokinetic parameters after single IV infusion* of MK-5890 in a Ph1 clinical study | ||||||
| Dose (mg/kg) | Cmax (µg/mL) | Tmax (hour) | AUC0–168 hours (hour*µg/mL) | Dose (mg) | Cmax (µg/mL) | Tmax† (hour) | AUC0–21 days (day×µg/mL) |
| 0.1 | 3.27±0.278 | 0.25±0.0 | 163±10.7 | 2 | 1.15 (175.3) | 1.50 (1.50–2.00) | 1.33 (88.7) |
| 3 | 84.1±4.10 | 0.63±0.38 | 7540±200 | 7 | 2.18 (40.1) | 1.50 (1.50–2.00) | 7.80 (53.6) |
| 30 | 1330±84.7 | 0.25±0.0 | 114000±7050 | 20 | 6.70 (51.6) | 2.00 (1.50–2.00) | 31.5 (93.2) |
| 70 | 21.6 (22.0) | 1.50 (1.50–2.00) | 154 (9.2) | ||||
| 200 | 67.8 (23.1) | 1.50 (1.50–2.00) | 527 (28.7) | ||||
| 700 | 105 (8.7) | 1.50 (1.50–1.50) | 1070 (0.1) | ||||
*MK-5890 delivered by intravenous infusion in human participants over a duration of 60–90 min.
†Median (min-max).
%GCV, % geometric coefficient of variation.